Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.

Fankhauser, Christian D; Christiansen, Ailsa J; Rothermundt, Christian; Cathomas, Richard; Wettstein, Marian S; Grossmann, Nico C; Grogg, Josias B; Templeton, Arnoud J; Hirschi-Blickenstorfer, Anita; Lorch, Anja; Gillessen, Silke; Moch, Holger; Beyer, Joerg; Hermanns, Thomas (2022). Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. British journal of cancer, 126(8), pp. 1140-1144. Springer Nature 10.1038/s41416-021-01643-z

Text s41416-021-01643-z.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (292kB) | Request a copy

BACKGROUND

MiR-371a-3p predicts the presence of a macroscopic non-teratomatous germ cell tumour (GCT). We hypothesised that miR-371a-3p can also detect recurrence during active surveillance (AS) of stage I GCT.

METHODS

We prospectively collected serum samples of 33 men. Relative expression of serum miR-371a-3p levels was determined at each follow-up visit using real-time quantitative reverse transcription-polymerase chain reaction.

RESULTS

Recurrence was detected using standard follow-up investigations in 10/33 patients (30%) after a median of 7 months. Directly after orchiectomy, miR-371a-3p levels were not elevated in any of the 15 patients with available post-orchiectomy samples. However, all ten recurring patients exhibited increasing miR-371a-3p levels during follow-up, while miR-371a-3p levels remained non-elevated in all but one patient without recurrence. MiR-371a-3p detected recurrences at a median of 2 months (range 0-5) earlier than standard follow-up investigations.

CONCLUSIONS

MiR-371a-3p levels immediately post orchiectomy are not predictive for recurrences and unfortunately cannot support decision-making for AS vs. adjuvant treatment. However, miR-371a-3p detects recurrences reliably and earlier than standard follow-up investigations. If this can be confirmed in larger cohorts, monitoring miR-371a-3p could replace surveillance imaging in seminomatous GCT and reduce the amount of imaging in non-seminomatous GCT. Earlier detection of disease recurrence may also reduce the overall treatment burden.

Interest & Impact

Downloads

1 since deposited on 24 Jan 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item